METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to outsmart advanced prostate cancer
Disease control Recruiting nowThis study is for men with a type of advanced prostate cancer that has spread and no longer responds to standard hormone therapy. It tests whether adding a new drug called SX-682 to the existing drug apalutamide is safe and can shrink tumors or slow the cancer. About 78 men will …
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase trial is testing a new treatment called TmPSMA-02 for men with metastatic castrate-resistant prostate cancer that has progressed after standard therapies. The treatment uses the patient's own immune cells (T cells) that are genetically modified to recognize and a…
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Could custom doses of prostate cancer radiation be safer and stronger?
Disease control Recruiting nowThis study tests whether giving a personalized dose of the drug 177Lu-PSMA-617 (Pluvicto) based on kidney function is safer and allows higher doses than the standard fixed dose. Sixty men with metastatic castration-resistant prostate cancer will receive either personalized or fix…
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Jean-Mathieu Beauregard • Aim: Disease control
Last updated Jun 26, 2026 14:37 UTC